Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ATM negative |
| Therapy | ART0380 + Irinotecan |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ATM negative | Advanced Solid Tumor | predicted - sensitive | ART0380 + Irinotecan | Phase Ib/II | Actionable | In a Phase I/II trial, treatment with the combination of Camptosar (irinotecan) and ART0380 in patients with advanced solid tumors was well tolerated and resulted in an objective response rate of 23% (13/57) overall, 45% (9/20) in ATM negative patients, 22% (4/18) with low ATM expression, and 0% (0/13) with high ATM expression (Cancer Res (2025) 85 (8_Supplement_2): CT267; NCT04657068). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT267: First results of ART0380 (an ATR kinase inhibitor) with low dose irinotecan in advanced or metastatic solid tumors | Full reference... |